Alnylam Pharmaceuticals (NASDAQ:ALNY) Given New $375.00 Price Target at Chardan Capital

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target trimmed by Chardan Capital from $425.00 to $375.00 in a report released on Friday. The firm currently has a buy rating on the biopharmaceutical company’s stock.

A number of other research firms also recently issued reports on ALNY. Jefferies Financial Group raised their price target on Alnylam Pharmaceuticals from $230.00 to $260.00 and gave the stock a “hold” rating in a research note on Tuesday, September 8th. UBS Group reaffirmed a “buy” rating and set a $329.00 price target (down from $550.00) on shares of Alnylam Pharmaceuticals in a research report on Friday. Wall Street Zen cut Alnylam Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Sunday, August 2nd. Barclays decreased their price objective on Alnylam Pharmaceuticals from $527.00 to $450.00 and set an “overweight” rating for the company in a report on Monday, August 3rd. Finally, Royal Bank Of Canada lowered their target price on shares of Alnylam Pharmaceuticals from $345.00 to $280.00 and set an “outperform” rating on the stock in a research report on Friday. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $317.95.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY stock opened at $165.00 on Friday. The stock’s 50-day moving average is $236.49 and its two-hundred day moving average is $286.19. The firm has a market cap of $22.08 billion, a price-to-earnings ratio of 8.57 and a beta of 0.28. Alnylam Pharmaceuticals has a 1 year low of $163.30 and a 1 year high of $479.79. The company has a debt-to-equity ratio of 0.75, a quick ratio of 2.99 and a current ratio of 3.05.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, October 29th. The biopharmaceutical company reported $16.26 EPS for the quarter, topping analysts’ consensus estimates of $1.66 by $14.60. Alnylam Pharmaceuticals had a return on equity of 246.94% and a net margin of 52.85%. The business had revenue of $1.46 billion for the quarter, compared to analysts’ expectations of $1.43 billion. During the same quarter in the previous year, the firm earned $2.90 earnings per share. The business’s revenue was up 16.7% compared to the same quarter last year. Analysts predict that Alnylam Pharmaceuticals will post 6.43 earnings per share for the current year.

Insider Transactions at Alnylam Pharmaceuticals

In related news, EVP Bryan Supran sold 1,758 shares of the stock in a transaction dated Friday, October 2nd. The shares were sold at an average price of $226.88, for a total transaction of $398,855.04. Following the completion of the transaction, the executive vice president directly owned 12,807 shares of the company’s stock, valued at $2,905,652.16. This represents a 12.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 0.86% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in ALNY. Toth Financial Advisory Corp purchased a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter worth approximately $25,000. Burkett Financial Services LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the third quarter valued at approximately $37,000. CoreCap Advisors LLC boosted its stake in shares of Alnylam Pharmaceuticals by 744.4% in the third quarter. CoreCap Advisors LLC now owns 152 shares of the biopharmaceutical company’s stock valued at $38,000 after buying an additional 134 shares in the last quarter. Keating Financial Advisory Services Inc. purchased a new stake in shares of Alnylam Pharmaceuticals in the second quarter valued at approximately $42,000. Finally, Root Financial Partners LLC acquired a new position in Alnylam Pharmaceuticals during the third quarter worth $48,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Key Stories Impacting Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Quarterly results exceeded expectations. Alnylam reported $16.26 in adjusted earnings per share versus the $1.66 consensus estimate, while revenue rose 16.7% year over year to $1.46 billion, slightly above forecasts. The company maintained its fiscal 2026 product-sales outlook and expects $4.2 billion–$4.5 billion in 2026 TTR sales. Alnylam Q3 earnings beat
• Positive Sentiment: Several analysts still see substantial long-term upside. Chardan Capital, TD Cowen, Goldman Sachs and RBC retained positive ratings, although they reduced their price targets. Their revised targets remain well above the current trading level. Chardan Capital rating
• Neutral Sentiment: Pipeline investment could support future growth but increases execution risk. Alnylam expanded the TRITON-CM nucresiran heart-disease study to approximately 2,250 patients while maintaining an anticipated launch around 2030. Management described its conviction in the program as high, but the longer timeline limits near-term revenue benefits. Alnylam TTR sales and trial update
• Negative Sentiment: Demand-growth concerns overshadowed the earnings beat. Slower Amvuttra patient starts and moderating U.S. Amvuttra and Onpattro sales growth raised concerns that the company’s core TTR business may be losing momentum. Management also acknowledged that it needs to improve execution, adding to uncertainty around the franchise. ALNY demand growth concerns
• Negative Sentiment: Analyst sentiment became more cautious. Bernstein downgraded ALNY to “market perform,” while Stifel cut its rating to “hold.” Multiple firms lowered price targets, including Bernstein from $376 to $199 and Goldman Sachs from $536 to $320, reflecting increased valuation and policy risks.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi). The company’s therapies are designed to silence specific genes involved in disease, with the goal of addressing the underlying causes of genetic and other serious conditions.

Alnylam’s marketed products include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.